NSAID–Gut Microbiota Interactions
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Nonsteroidal anti-inflammatory drugs (NSAID)s relieve pain, inflammation, and fever by inhibiting the activity of cyclooxygenase isozymes (COX-1 and COX-2). Despite their clinical efficacy, NSAIDs can cause gastrointestinal (GI) and cardiovascular (CV) complications. Moreover, NSAID use is characterized by a remarkable individual variability in the extent of COX isozyme inhibition, therapeutic efficacy, and incidence of adverse effects. The interaction between the gut microbiota and host has emerged as a key player in modulating host physiology, gut microbiota-related disorders, and metabolism of xenobiotics. Indeed, host-gut microbiota dynamic interactions influence NSAID disposition, therapeutic efficacy, and toxicity. The gut microbiota can directly cause chemical modifications of the NSAID or can indirectly influence its absorption or metabolism by regulating host metabolic enzymes or processes, which may have consequences for drug pharmacokinetic and pharmacodynamic properties. NSAID itself can directly impact the composition and function of the gut microbiota or indirectly alter the physiological properties or functions of the host which may, in turn, precipitate in dysbiosis. Thus, the complex interconnectedness between host-gut microbiota and drug may contribute to the variability in NSAID response and ultimately influence the outcome of NSAID therapy. Herein, we review the interplay between host-gut microbiota and NSAID and its consequences for both drug efficacy and toxicity, mainly in the GI tract. In addition, we highlight progress towards microbiota-based intervention to reduce NSAID-induced enteropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
The gut microbiota--masters of host development and physiology
Sommer, F., & Bäckhed, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2974 · Cited by 3,681
Population-level analysis of gut microbiome variation
Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., Kurilshikov, A., Bonder, M. J., Valles-Colomer, M., Vandeputte, D., et al. (2016) · Science · doi:10.1126/science.aad3503 · Cited by 2,400 · cited 1×
“Medication has recently emerged as one of the most influential determinants of the gut microbiota composition and activity (Falony et al., 2016; Zhernakova et al., 2016; Maier et al., 2018).”
BackgroundPopulation-based metagenomics analysis reveals markers for gut microbiome composition and diversity
Zhernakova, A., Kurilshikov, A., Bonder, M. J., Tigchelaar, E. F., Schirmer, M., Vatanen, T., Mujagic, Z., Vila, A. V., Falony, G., Vieira-Silva, S., et al. (2016) · Science · doi:10.1126/science.aad3369 · Cited by 1,914 · cited 1×
“Medication has recently emerged as one of the most influential determinants of the gut microbiota composition and activity (Falony et al., 2016; Zhernakova et al., 2016; Maier et al., 2018).”
BackgroundExtensive impact of non-antibiotic drugs on human gut bacteria
Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., et al. (2018) · Nature · doi:10.1038/nature25979 · Cited by 1,905
Proton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371
How informative is the mouse for human gut microbiota research?
Nguyen, T. L. A., Vieira-Silva, S., Liston, A., & Raes, J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017400 · Cited by 1,334 · cited 1×
“This is due to many factors, including species-specific differences in gastrointestinal anatomy, physiology and microbiota profiles; reduced microbiota diversity and dynamics due to laboratory conditions; and genetic similarity of used rodent strains (Nguyen et al., 2015).”
BackgroundSelective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310
Chemical transformation of xenobiotics by the human gut microbiota
Koppel, N., Maini Rekdal, V., & Balskus, E. P. (2017) · Science · doi:10.1126/science.aag2770 · Cited by 1,080
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
Xenobiotics shape the physiology and gene expression of the active human gut microbiome
Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013) · Cell · doi:10.1016/j.cell.2012.10.052 · Cited by 811
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753 · cited 1×
“L-dopa degradation in human stool samples can be predicted predominantly by tyrosine decarboxylase gene expression and abundance of Enterococcus faecalis and Eggerthella lenta (Maini Rekdal et al., 2019).”
BackgroundPredicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J. (2013) · Science · doi:10.1126/science.1235872 · Cited by 704
Gut microbiome interactions with drug metabolism, efficacy, and toxicity
Wilson, I. D., & Nicholson, J. K. (2017) · Translational Research · doi:10.1016/j.trsl.2016.08.002 · Cited by 656 · cited 3×
“The gut microbiota can have direct and indirect effects on drug absorption, distribution, metabolism and excretion, and consequently affect drug efficacy and toxicity (Wilson and Nicholson, 2017).”
BackgroundInfluentialThe gastrointestinal microbiota as a site for the biotransformation of drugs
Sousa, T., Paterson, R., Moore, V., Carlsson, A., Abrahamsson, B., & Basit, A. W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.009 · Cited by 618
Collins, S. M., & Bercik, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.075 · Cited by 612
Kim, Y.-G., Udayanga, K. G. S., Totsuka, N., Weinberg, J. B., Núñez, G., & Shibuya, A. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2013.12.010 · Cited by 366
Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-analysis
Lo, W., & Chan, W. W. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.12.011 · Cited by 353 · cited 1×
“…bacterial overgrowth (SIBO) risk among adult users of PPIs vs nonusers indicates that the use of PPIs is associated with SIBO, a condition that can cause excessive fermentation and inflammation, leading to a variety of clinical complaints including bloating and diarrhea (Lo and Chan, 2013).”
BackgroundThe gut microbiome: an orchestrator of xenobiotic metabolism
Collins, S. L., & Patterson, A. D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.001 · Cited by 348
The influence of non-steroidal anti-inflammatory drugs on the gut microbiome
Rogers, M. A. M., & Aronoff, D. M. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.10.003 · Cited by 346 · cited 2×
“NSAID users can present different gut microbiota profiles from that of nonusers, as do users of specific types of NSAIDs (Rogers and Aronoff, 2016).”
BackgroundResistance of germfree rats to indomethacin-induced intestinal lesions
Robert, A., & Asano, T. (1977) · Prostaglandins · doi:10.1016/0090-6980(77)90178-2 · Cited by 312 · cited 1×
“For example, germ-free rats are resistant to indomethacin-induced enteropathy, in contrast germ-free rats colonized with Escherichia coli develop severe lesions in the gut (Robert and Asano, 1977).”
BackgroundAn atlas of β-glucuronidases in the human intestinal microbiome
Pollet, R. M., D'Agostino, E. H., Walton, W. G., Xu, Y., Little, M. S., Biernat, K. A., Pellock, S. J., Patterson, L. M., Creekmore, B. C., Isenberg, H. N., et al. (2017) · Structure · doi:10.1016/j.str.2017.05.003 · Cited by 289
Digoxin-Inactivating Bacteria: Identification in Human Gut Flora
Dobkin, J. F., Saha, J. R., Butler, V. P., Neu, H. C., & Lindenbaum, J. (1983) · Science · doi:10.1126/science.6836275 · Cited by 259
Langenbach, R., Loftin, C., Lee, C., & Tiano, H. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00158-6 · Cited by 230 · cited 1×
“The gastric pH is lower in Cox-1 deficient mice than in wild-type and Cox-2 deficient mice (Langenbach et al., 1999), consistent with the Cox-1 dependent secretion of acid and/or bicarbonate in the stomach.”
BackgroundGut microbiota composition is associated with polypharmacy in elderly hospitalized patients
Ticinesi, A., Milani, C., Lauretani, F., Nouvenne, A., Mancabelli, L., Lugli, G. A., Turroni, F., Duranti, S., Mangifesta, M., Viappiani, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10734-y · Cited by 211
LoGuidice, A., Wallace, B. D., Bendel, L., Redinbo, M. R., & Boelsterli, U. A. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.191122 · Cited by 197
Saitta, K. S., Zhang, C., Lee, K. K., Fujimoto, K., Redinbo, M. R., & Boelsterli, U. A. (2014) · Xenobiotica · doi:10.3109/00498254.2013.811314 · Cited by 165 · cited 2×
“…2011; Mizukami et al., 2011; Kurokawa et al., 2014; Watanabe et al., 2015; Ota et al., 2016 b-glucuronidase inhibitors Mouse LoGuidice et al., 2012; Saitta et al., 2014 Probiotics Rat Kinouchi et al., 1998; Watanabe et al., 2009; Syer et al., 2015; Fornai et al., 2020 Human Endo et al., 2011; de…”
BackgroundUejima, M., Kinouchi, T., Kataoka, K., Hiraoka, I., & Ohnishi, Y. (1996) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1996.tb01108.x · Cited by 110
NSAID enteropathy and bacteria: a complicated relationship
Syer, S. D., Blackler, R. W., Martin, R., de Palma, G., Rossi, L., Verdu, E., Bercik, P., Surette, M. G., Aucouturier, A., Langella, P., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-014-1032-1 · Cited by 80
Terán-Ventura, E., Aguilera, M., Vergara, P., & Martínez, V. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.02.001 · Cited by 59 · cited 1×
“intestinal inflammation, characterized by upregulation of Tolllike receptor (TLR)-2 and -4 in the intestine and increases the abundance of Bacteroides and Enterobacteriaceae in the ileum and cecum-colon and Clostridium the in ileum of male rats (Terán-Ventura et al., 2014).”
BackgroundUnderstanding and Modulating Mammalian-Microbial Communication for Improved Human Health
Mani, S., Boelsterli, U. A., & Redinbo, M. R. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140007 · Cited by 48
Metadata
- Authors
- Maseda, D., & Ricciotti, E.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-07
- Volume
- 11
- Pages
- 1153-1153
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3048174675
- Cited by
- 159
- References
- 31
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.